Abstract
Post-hematopoietic stem cell transplantation (HSCT) maintenance therapy using azacitidine and prophylactic donor lymphocyte infusions (DLI) was implemented for high-risk acute myeloid leukemia. Azacitidine was started on day +60 as a 5 day course every 28 days for 6 cycles. DLI was given every 6 weeks for 3 doses starting after day +120. Ten patients were treated on this protocol. With a 90% one-year disease free survival, we report this post-HSCT maintenance therapy is feasible, safe, and well tolerated.
Author supplied keywords
Cite
CITATION STYLE
Huschart, E., Miller, H., Salzberg, D., Campbell, C., Beebe, K., Schwalbach, C., … Ngwube, A. (2020). Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia. Pediatric Hematology and Oncology, 38(2), 154–160. https://doi.org/10.1080/08880018.2020.1829220
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
